Short-Course Treatment With Gefitinib Enhances Curative Potential of Radiation Therapy in a Mouse Model of Human Non-Small Cell Lung Cancer
- 1 March 2014
- journal article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 88 (4) , 947-954
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Stereotactic ablative radiotherapy in the UK: current status and developmentsBritish Journal of Radiology, 2013
- The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing ParadigmsCancer Research and Treatment, 2011
- Factors determining DNA double‐strand break repair pathway choice in G2 phaseThe EMBO Journal, 2011
- Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutatedMolecular Cancer, 2010
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- Role of Cell Cycle in Epidermal Growth Factor Receptor Inhibitor-Mediated RadiosensitizationCancer Research, 2009
- γH2AX and cancerNature Reviews Cancer, 2008
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004